ReviewEuropean journal of nuclear medicine and molecular imaging2018
Assessing FDG-PET diagnostic accuracy studies to develop recommendations for clinical use in dementia.
Review in European journal of nuclear medicine and molecular imaging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.
- Diagnostic performance of molecular imaging methods in predicting the progression from mild cognitive impairment to dementia: an updated systematic review.European journal of nuclear medicine and molecular imaging · 2024Pooled it
- Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives.European journal of nuclear medicine and molecular imaging · 2021Pooled it
- Biomarker-Based Diagnosis and Care Pathways for Alzheimer's Disease in the Era of Disease-Modifying Treatments: A Consensus Statement by Belgian Experts.European journal of neurology · 2026Article
- Validating plasma biomarkers for distinguishing neurodegenerative and psychiatric disorders.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- How the use of FDG PET is improving the diagnosis of dementia in a reference center in Recife, Brazil.Arquivos de neuro-psiquiatria · 2025Article
- Why should academia care about the Target Product Profile?Journal of translational medicine · 2024Article
- Translational process.Journal of translational medicine · 2023Article
- The strategic biomarker roadmap for the validation of Alzheimer's diagnostic biomarkers: methodological update.European journal of nuclear medicine and molecular imaging · 2021Article
- Clinical validity of increased cortical uptake of [European journal of nuclear medicine and molecular imaging · 2021Review
- Clinical impact ofEuropean journal of nuclear medicine and molecular imaging · 2021Article
- Views on Early Diagnosis of Alzheimer's Disease Among Dutch Physicians: A Qualitative Interview Study.Journal of Alzheimer's disease : JAD · 2021Article
- Nuclear medical imaging as part of dementia diagnostics in psychiatric day-care clinics and inpatient care settings.Aging clinical and experimental research · 2020Article
- Impact of amyloid-PET in daily clinical management of patients with cognitive impairment fulfilling appropriate use criteria.Medicine · 2019Observational
- Clinical utility of FDG-PET for the clinical diagnosis in MCI.European journal of nuclear medicine and molecular imaging · 2018Review
- Automated assessment of FDG-PET for differential diagnosis in patients with neurodegenerative disorders.European journal of nuclear medicine and molecular imaging · 2018Review
- Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia.European journal of nuclear medicine and molecular imaging · 2018Review
- Diagnostic utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in asymptomatic subjects at increased risk for Alzheimer's disease.European journal of nuclear medicine and molecular imaging · 2018Review
- Diagnostic utility of FDG-PET in the differential diagnosis between different forms of primary progressive aphasia.European journal of nuclear medicine and molecular imaging · 2018Article
- Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington's disease.European journal of nuclear medicine and molecular imaging · 2018Review
- Clinical utility of FDG PET in Parkinson's disease and atypical parkinsonism associated with dementia.European journal of nuclear medicine and molecular imaging · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 3 countries.
Funding
Abstract
backgroundFDG-PET is frequently used as a marker of synaptic damage to diagnose dementing neurodegenerative disorders. We aimed to adapt the items of evidence quality to FDG-PET diagnostic studies, and assess the evidence available in current literature to assist Delphi decisions for European recommendations for clinical use.
methodsBased on acknowledged methodological guidance, we defined the domains, specific to FDG-PET, required to assess the quality of evidence in 21 literature searches addressing as many Population Intervention Comparison Outcome (PICO) questions. We ranked findings for each PICO and fed experts making Delphi decisions for recommending clinical use.
resultsAmong the 1435 retrieved studies, most lacked validated measures of test performance, an adequate gold standard, and head-to-head comparison of FDG-PET and clinical diagnosis, and only 58 entered detailed assessment. Only two studies assessed the accuracy of the comparator (clinical diagnosis) versus any kind of gold-/reference-standard. As to the index-test (FDG-PET-based diagnosis), an independent gold-standard was available in 24% of the examined papers; 38% used an acceptable reference-standard (clinical follow-up); and 38% compared FDG-PET-based diagnosis only to baseline clinical diagnosis. These methodological limitations did not allow for deriving recommendations from evidence. DISCUSSION: An incremental diagnostic value of FDG-PET versus clinical diagnosis or lack thereof cannot be derived from the current literature. Many of the observed limitations may easily be overcome, and we outlined them as research priorities to improve the quality of current evidence. Such improvement is necessary to outline evidence-based guidelines. The available data were anyway provided to expert clinicians who defined interim recommendations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.